Search research articles
Contact Us
Filters
Showing results (21-30 of 31) with videos related to
Page
of 4
Sort By:
Journal of Immunotherapy and Precision Oncology
|
August 29, 2022
Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience
Dylan J Martini, T Anders Olsen, Subir Goyal, et al.
The Oncologist
|
February 26, 2021
Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors
Jacqueline T Brown, Yuan Liu, Julie M Shabto, et al.
The Oncologist
|
February 3, 2026
Clinical outcomes of Lutetium-177-PSMA-617 in a racially diverse cohort of patients with metastatic castration-resistant prostate cancer
Margo Brooke Gerke, Akshay Bedmutha, Angelo Marra, et al.
Frontiers in Oncology
|
July 5, 2021
Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade
T Anders Olsen, Dylan J Martini, Subir Goyal, et al.
Frontiers in Oncology
|
July 26, 2021
Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors
Dylan J Martini, T Anders Olsen, Subir Goyal, et al.
The Oncologist
|
June 7, 2023
Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors
Gregory E Sanda, Julie M Shabto, Subir Goyal, et al.
Clinical Genitourinary Cancer
|
December 19, 2021
Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients
Dylan J Martini, Sean T Evans, Yuan Liu, et al.
The Oncologist
|
June 22, 2021
Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
Dylan J Martini, Subir Goyal, Yuan Liu, et al.
The Oncologist
|
August 3, 2021
Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors
Dylan J Martini, Julie M Shabto, Subir Goyal, et al.
Research Square
|
August 16, 2024
Neoadjuvant cabozantinib restores CD8+ T cells in patients with locally advanced non-metastatic clear cell renal cell carcinoma: a phase 2 trial
Mehmet A Bilen, BaoHan T Vo, Yuan Liu, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 31) with videos related to
Sort By:
Page
of 4
Journal of Immunotherapy and Precision Oncology
|
August 29, 2022
Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience
Dylan J Martini, T Anders Olsen, Subir Goyal, et al.
The Oncologist
|
February 26, 2021
Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors
Jacqueline T Brown, Yuan Liu, Julie M Shabto, et al.
The Oncologist
|
February 3, 2026
Clinical outcomes of Lutetium-177-PSMA-617 in a racially diverse cohort of patients with metastatic castration-resistant prostate cancer
Margo Brooke Gerke, Akshay Bedmutha, Angelo Marra, et al.
Frontiers in Oncology
|
July 5, 2021
Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade
T Anders Olsen, Dylan J Martini, Subir Goyal, et al.
Frontiers in Oncology
|
July 26, 2021
Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors
Dylan J Martini, T Anders Olsen, Subir Goyal, et al.
The Oncologist
|
June 7, 2023
Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors
Gregory E Sanda, Julie M Shabto, Subir Goyal, et al.
Clinical Genitourinary Cancer
|
December 19, 2021
Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients
Dylan J Martini, Sean T Evans, Yuan Liu, et al.
The Oncologist
|
June 22, 2021
Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
Dylan J Martini, Subir Goyal, Yuan Liu, et al.
The Oncologist
|
August 3, 2021
Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors
Dylan J Martini, Julie M Shabto, Subir Goyal, et al.
Research Square
|
August 16, 2024
Neoadjuvant cabozantinib restores CD8+ T cells in patients with locally advanced non-metastatic clear cell renal cell carcinoma: a phase 2 trial
Mehmet A Bilen, BaoHan T Vo, Yuan Liu, et al.
Page
of 4